2024
Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
McQuaid C, Ryckman T, Menzies N, White R, Cohen T, Kendall E. Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1571-1579. PMID: 39043388, PMCID: PMC11286077, DOI: 10.3201/eid3008.240541.Peer-Reviewed Original ResearchConceptsResistance to novel drugsStandard of careAntimicrobial resistanceIncreasing prevalence of antimicrobial resistancePrevalence of antimicrobial resistanceIncreased prevalenceDrug susceptibility testingCompare treatment outcomesFirst-line drugsNovel drugsTB patient cohortTreatment regimensPatient cohortNew tuberculosisRegimensTreatment outcomesComponent drugsDrugCohortTuberculosisCDCUniversal useClinicCarePrevalence
2009
What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae?
Colijn C, Cohen T, Fraser C, Hanage W, Goldstein E, Givon-Lavi N, Dagan R, Lipsitch M. What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae? Journal Of The Royal Society Interface 2009, 7: 905-919. PMID: 19940002, PMCID: PMC2871802, DOI: 10.1098/rsif.2009.0400.Peer-Reviewed Original ResearchConceptsDrug-resistant strainsStreptococcus pneumoniaeInfectious diseasesDrug-susceptible strainsHigher reproduction numberCent prevalenceSubstantial prevalencePersistent coexistenceDrug resistanceMultiple infectionsAntimicrobial useResistant strainsBacterial spreadAntimicrobial resistancePrevalenceDiseasePneumoniaeOutcomesReproduction numberTreatmentHost interactionsPathogensCoinfection